Inspire Medical Systems, Inc. (INSP) Stock Analysis and Metrics

Inspire Medical Systems

NYSE: INSP

$49.19 ▼ -1.62 (-3.19%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap1.46 Bn

P/E11.12

P/S1.59

Div. Yield0.00

Revenue Growth (1y) (Qtr)1.62

Add ratio to table…

About

Inspire Medical Systems Inc is a medical technology company that develops and commercializes innovative minimally invasive solutions for patients with obstructive sleep apnea. Its flagship product the Inspire system is the first neurostimulation therapy to receive FDA approval European Union MDR approval and Japan approval for treating moderate to severe obstructive sleep apnea. The Inspire system uses a closed loop algorithm that senses breathing and delivers mild hypoglossal nerve stimulation to keep the airway open during sleep. More than 125000 patients have received Inspire therapy in the United States Europe and Asia since its launch. The device obtained premarket approval from the FDA in 2014 a CE mark in Europe in 2010 and regulatory clearance in Japan in 2018.

Inspire Medical Systems generates revenue primarily by selling the Inspire system to hospitals and ambulatory surgery centers. In the United States and select European markets the company uses a direct sales force to call on ENT physicians and sleep centers. In Japan and Singapore Inspire therapy is sold through independent distributors. Revenue also comes from related services such as patient support programs prior authorization assistance and the SleepSync cloud based platform. Hospitals and ambulatory surgery centers bill third party payors including commercial insurers Medicare and Medicaid for the procedure and device costs.

Inspire Medical Systems holds a first mover advantage in the neurostimulation space for obstructive sleep apnea. It is the only company with an FDA approved closed loop system that senses respiration and delivers timed hypoglossal nerve stimulation. Competitors include Nyxoah which offers an open loop bilateral stimulation device and LivaNova which has submitted a hypoglossal nerve stimulation device for FDA review. Traditional continuous positive airway pressure providers such as ResMed Philips and Fisher & Paykel remain the first line therapy but face compliance challenges. Invasive surgical options like uvulopalatopharyngoplasty and maxillomandibular advancement serve as alternative second line treatments. Inspire differentiates itself through a robust body of clinical evidence including over 385 peer reviewed publications long term data from the STAR trial and real world results from the ADHERE registry. The company also benefits from a strong intellectual property portfolio with 119 issued US patents 83 issued foreign patents and numerous pending applications. Its market access team helps secure prior authorizations and coverage policies with commercial payors and Medicare facilitating reimbursement for patients and providers. Direct to consumer marketing and patient education programs further drive demand and brand awareness.

Inspire Medical Systems serves hospitals and ambulatory surgery centers that perform the implantation procedure. These customers are located throughout the United States in selected European countries and in Japan and Singapore through distributor partners. The company also works closely with ENT physicians sleep centers and referral sources who identify appropriate patients for Inspire therapy. While specific customer names are not disclosed the base includes academic medical centers community hospitals and independent surgery centers. Patients who have failed or cannot tolerate continuous positive airway pressure therapy represent the target end user group for the Inspire system.

Investment Thesis

▲ Bull case

The company is positioned to capture a significant acceleration in revenue growth once the Inspire V transition is fully completed as management has already achieved SleepSync implementation at over fifty% of United States centers and expects near complete adoption by the end of the third quarter. This progress removes a major operational bottleneck that had delayed patient flow and allowed centers to continue relying on the older Inspire IV system. With the software and training barriers largely resolved the addressable market for the next generation device will expand rapidly as more surgeons gain confidence in the streamlined implantation process that eliminates the need for the pressure sensing lead. The resulting increase in procedural capacity is already evident in the limited release sites where implant volumes have risen more than twenty% year over year demonstrating a tangible uplift that can be replicated across the broader network as rollout continues.
Reimbursement headwinds that weighed on second quarter performance are set to reverse as the Centers for Medicare and Medicaid Services proposed OPPS rule for 2026 includes a meaningful increase in hospital and ambulatory surgical center payments for CPT code 64568 alongside an eleven% rise in surgeon reimbursement. If finalized as anticipated these higher rates will improve the economics of treating Medicare patients with Inspire V and remove the perceived disadvantage that some physicians cited regarding lower payment relative to the legacy code. The improved payment per case combined with reduced operative time creates a favorable margin environment that should encourage higher procedure volumes especially among high volume implanters who are sensitive to both time and compensation. This reimbursement tailwind is expected to take effect at the start of 2026 providing a clear catalyst for accelerated growth beyond the current fiscal year.
Clinical evidence supporting the Inspire platform continues to strengthen with the upcoming publication of the PREDICTOR manuscript which proposes an algorithm using body mass index and neck circumference to predict eligibility thereby eliminating the need for a drug induced sleep endoscopy for the majority of candidates. By reducing the diagnostic barrier the algorithm has the potential to increase the pool of eligible patients and shorten the time from consultation to implant thereby accelerating patient flow. Early data from the Singapore study also shows a twenty% reduction in surgical times which translates directly into greater operating room capacity and the ability to treat more patients without additional capital investment. These clinical advancements reinforce the long term value proposition of the hypoglossal nerve stimulation platform and support sustained premium pricing power.
Management has signaled a deliberate increase in direct to consumer marketing and footprint expansion in the second half of the year after purposely restraining these initiatives during the first half to focus on the Inspire V launch. The resumption of DTC spend is projected to grow over twenty% year over year reaching approximately one hundred fifteen million dollars which should boost patient awareness and drive higher inquiry volumes through the Advisor Care program. Simultaneously the addition of new territories and field clinical representatives will expand the geographic reach of the sales force enabling the company to capture demand in underserved markets. These investments are expected to generate a compounding effect where higher patient awareness feeds more leads to the expanded provider network creating a virtuous cycle of growth.
The company’s strong liquidity position with over four hundred ten million dollars in cash and investments provides ample flexibility to fund the aforementioned growth initiatives without relying on external financing. This financial cushion reduces the risk of execution delays due to capital constraints and allows the firm to absorb any short term fluctuations in operating performance while pursuing strategic investments. A solid balance sheet also supports potential opportunistic actions such as acquisitions or partnerships that could further enhance the technology platform or expand geographic coverage. The combination of internal cash generation and conservative leverage creates a resilient foundation for long term shareholder value creation.

The company is positioned to capture a significant acceleration in revenue growth once the Inspire V transition is fully completed as management has already achieved SleepSync implementation at over fifty% of United States centers and expects near complete adoption by the end of the third quarter. This progress removes a major operational bottleneck that had delayed patient flow and allowed centers to continue relying on the older Inspire IV system. With the software and training barriers largely resolved the addressable market for the next generation device will expand rapidly as more surgeons gain confidence in the streamlined implantation process that eliminates the need for the pressure sensing lead. The resulting increase in procedural capacity is already evident in the limited release sites where implant volumes have risen more than twenty% year over year demonstrating a tangible uplift that can be replicated across the broader network as rollout continues.
Reimbursement headwinds that weighed on second quarter performance are set to reverse as the Centers for Medicare and Medicaid Services proposed OPPS rule for 2026 includes a meaningful increase in hospital and ambulatory surgical center payments for CPT code 64568 alongside an eleven% rise in surgeon reimbursement. If finalized as anticipated these higher rates will improve the economics of treating Medicare patients with Inspire V and remove the perceived disadvantage that some physicians cited regarding lower payment relative to the legacy code. The improved payment per case combined with reduced operative time creates a favorable margin environment that should encourage higher procedure volumes especially among high volume implanters who are sensitive to both time and compensation. This reimbursement tailwind is expected to take effect at the start of 2026 providing a clear catalyst for accelerated growth beyond the current fiscal year.
Clinical evidence supporting the Inspire platform continues to strengthen with the upcoming publication of the PREDICTOR manuscript which proposes an algorithm using body mass index and neck circumference to predict eligibility thereby eliminating the need for a drug induced sleep endoscopy for the majority of candidates. By reducing the diagnostic barrier the algorithm has the potential to increase the pool of eligible patients and shorten the time from consultation to implant thereby accelerating patient flow. Early data from the Singapore study also shows a twenty% reduction in surgical times which translates directly into greater operating room capacity and the ability to treat more patients without additional capital investment. These clinical advancements reinforce the long term value proposition of the hypoglossal nerve stimulation platform and support sustained premium pricing power.
Management has signaled a deliberate increase in direct to consumer marketing and footprint expansion in the second half of the year after purposely restraining these initiatives during the first half to focus on the Inspire V launch. The resumption of DTC spend is projected to grow over twenty% year over year reaching approximately one hundred fifteen million dollars which should boost patient awareness and drive higher inquiry volumes through the Advisor Care program. Simultaneously the addition of new territories and field clinical representatives will expand the geographic reach of the sales force enabling the company to capture demand in underserved markets. These investments are expected to generate a compounding effect where higher patient awareness feeds more leads to the expanded provider network creating a virtuous cycle of growth.
The company’s strong liquidity position with over four hundred ten million dollars in cash and investments provides ample flexibility to fund the aforementioned growth initiatives without relying on external financing. This financial cushion reduces the risk of execution delays due to capital constraints and allows the firm to absorb any short term fluctuations in operating performance while pursuing strategic investments. A solid balance sheet also supports potential opportunistic actions such as acquisitions or partnerships that could further enhance the technology platform or expand geographic coverage. The combination of internal cash generation and conservative leverage creates a resilient foundation for long term shareholder value creation.

▼ Bear case

The Inspire V rollout remains dependent on the completion of SleepSync implementation and associated training contracting and onboarding steps at individual centers a process that has already proven slower than anticipated and could extend beyond the current fiscal year. Although management reports that over fifty% of United States centers have completed the SleepSync setup the remaining centers may face prolonged IT department approvals or internal resource constraints that delay full adoption. Any further slippage in completing these prerequisites would continue to shift patient procedures to the legacy Inspire IV system prolonging inventory destocking pressures and limiting the realization of the expected capacity uplift from the next generation platform. Consequently the anticipated acceleration in revenue growth could be postponed resulting in a longer period of sub par performance relative to historical trends.
Inventory destocking of the older Inspire IV devices represents a persistent headwind that management has acknowledged will continue to affect the second half of 2025 as the company works to transition customers to the Inspire V system. While the second quarter saw limited destocking because most units sold were Inspire IV the accumulated inventory will need to be liquidated as centers adopt the new device creating a potential drag on revenue growth and gross margin. If the pace of Inspire V adoption does not meet expectations the excess Inspire IV stock could lead to increased promotional discounting or write downs which would erode profitability. This inventory overhang introduces uncertainty into the company’s ability to achieve its revised full year revenue guidance of nine hundred to nine hundred ten million dollars.
Reimbursement dynamics for Medicare patients remain a source of risk despite the recent software update that enables billing for CPT code 64568 as some high volume physicians have expressed concern that the lower payment rate under the new code makes treating Medicare beneficiaries less attractive relative to private pay cases. Although management argues that the reduction in operative time offsets the payment difference the perception of reduced compensation could lead to selective case allocation where physicians prioritize procedures with higher reimbursement thereby limiting volume growth among the Medicare population. If this sentiment persists or widens it could undermine the expected benefit from the proposed OPPS rule increases and constrain overall procedure growth particularly given that a substantial portion of Inspire’s patient base relies on Medicare coverage. This could lead to a slower adoption of Inspire V among Medicare patients and limit the upside from the anticipated reimbursement improvements.
Operating expenses are set to rise significantly in the second half of the year as the company increases direct to consumer marketing spend and expands its sales footprint a shift that has already been reflected in the revised earnings per share guidance of zero point forty to zero point fifty dollars. The increase in sales and marketing expenditures combined with accelerated non cash stock based compensation related to retirement eligible employees could pressure operating margins especially if revenue growth fails to meet the projected twelve to thirteen% year over year increase. Higher operating leverage means that any shortfall in top line performance would translate into a disproportionately larger impact on bottom line results raising the risk of continued net losses or subdued profitability through the remainder of 2025 and into 2026. Should revenue growth fall short of expectations the combined effect of higher expenses and lower income could result in continued net losses and strain the company’s profitability outlook.
Accounts receivable experienced a notable increase at the end of the second quarter due to the transition to a new automated billing service which caused a temporary delay in invoice delivery and a back end loaded June that contributed to higher outstanding balances. While management expects the timing issue to be resolved in the third quarter any prolonged delays in collections could affect cash flow and increase the reliance on the existing cash reserve to fund operations. Persistent receivables elongation might also signal underlying challenges in customer payment behavior or inefficiencies in the new billing platform that could recur in future periods thereby adding working capital pressure to the business. An elongated collection cycle could also increase the need for external financing or limit the company’s ability to reinvest cash into growth initiatives.

The Inspire V rollout remains dependent on the completion of SleepSync implementation and associated training contracting and onboarding steps at individual centers a process that has already proven slower than anticipated and could extend beyond the current fiscal year. Although management reports that over fifty% of United States centers have completed the SleepSync setup the remaining centers may face prolonged IT department approvals or internal resource constraints that delay full adoption. Any further slippage in completing these prerequisites would continue to shift patient procedures to the legacy Inspire IV system prolonging inventory destocking pressures and limiting the realization of the expected capacity uplift from the next generation platform. Consequently the anticipated acceleration in revenue growth could be postponed resulting in a longer period of sub par performance relative to historical trends.
Inventory destocking of the older Inspire IV devices represents a persistent headwind that management has acknowledged will continue to affect the second half of 2025 as the company works to transition customers to the Inspire V system. While the second quarter saw limited destocking because most units sold were Inspire IV the accumulated inventory will need to be liquidated as centers adopt the new device creating a potential drag on revenue growth and gross margin. If the pace of Inspire V adoption does not meet expectations the excess Inspire IV stock could lead to increased promotional discounting or write downs which would erode profitability. This inventory overhang introduces uncertainty into the company’s ability to achieve its revised full year revenue guidance of nine hundred to nine hundred ten million dollars.
Reimbursement dynamics for Medicare patients remain a source of risk despite the recent software update that enables billing for CPT code 64568 as some high volume physicians have expressed concern that the lower payment rate under the new code makes treating Medicare beneficiaries less attractive relative to private pay cases. Although management argues that the reduction in operative time offsets the payment difference the perception of reduced compensation could lead to selective case allocation where physicians prioritize procedures with higher reimbursement thereby limiting volume growth among the Medicare population. If this sentiment persists or widens it could undermine the expected benefit from the proposed OPPS rule increases and constrain overall procedure growth particularly given that a substantial portion of Inspire’s patient base relies on Medicare coverage. This could lead to a slower adoption of Inspire V among Medicare patients and limit the upside from the anticipated reimbursement improvements.
Operating expenses are set to rise significantly in the second half of the year as the company increases direct to consumer marketing spend and expands its sales footprint a shift that has already been reflected in the revised earnings per share guidance of zero point forty to zero point fifty dollars. The increase in sales and marketing expenditures combined with accelerated non cash stock based compensation related to retirement eligible employees could pressure operating margins especially if revenue growth fails to meet the projected twelve to thirteen% year over year increase. Higher operating leverage means that any shortfall in top line performance would translate into a disproportionately larger impact on bottom line results raising the risk of continued net losses or subdued profitability through the remainder of 2025 and into 2026. Should revenue growth fall short of expectations the combined effect of higher expenses and lower income could result in continued net losses and strain the company’s profitability outlook.
Accounts receivable experienced a notable increase at the end of the second quarter due to the transition to a new automated billing service which caused a temporary delay in invoice delivery and a back end loaded June that contributed to higher outstanding balances. While management expects the timing issue to be resolved in the third quarter any prolonged delays in collections could affect cash flow and increase the reliance on the existing cash reserve to fund operations. Persistent receivables elongation might also signal underlying challenges in customer payment behavior or inefficiencies in the new billing platform that could recur in future periods thereby adding working capital pressure to the business. An elongated collection cycle could also increase the need for external financing or limit the company’s ability to reinvest cash into growth initiatives.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Devices

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ABT	Abbott Laboratories	201.40 Bn	27.98	4.46	34.05 Bn
2	SYK	Stryker Corp	122.29 Bn	36.60	4.84	14.72 Bn
3	MDT	Medtronic plc	105.01 Bn	21.73	2.89	27.96 Bn
4	BSX	Boston Scientific Corp	64.81 Bn	18.16	3.14	11.03 Bn
5	EW	Edwards Lifesciences Corp	55.28 Bn	2,354.76	8.77	0.60 Bn
6	DXCM	Dexcom Inc	29.06 Bn	29.17	6.03	-
7	PHG	Koninklijke Philips Nv	29.02 Bn	22.06	1.42	9.48 Bn
8	GEHC	GE HealthCare Technologies Inc.	28.27 Bn	14.30	1.35	10.14 Bn

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Geographical Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password